Welcome to our dedicated page for Asahi Kaisei Adr news (Ticker: AHKSY), a resource for investors and traders seeking the latest updates and insights on Asahi Kaisei Adr stock.
News for ASAHI KAISEI CRP UNSP/ADR (AHKSY) reflects the breadth of Asahi Kasei Corporation’s activities across its Healthcare, Homes, and Material sectors. Company announcements highlight how this diversified manufacturer is reshaping its portfolio, advancing medical technologies, and developing new materials and electronic components.
In Healthcare, recent news features ZOLL Medical, an Asahi Kasei company, and its LifeVest wearable cardioverter defibrillator. Updates describe launches of next-generation LifeVest systems and garments, along with references to clinical evidence and AI-enhanced algorithms designed to reduce false alarms. Asahi Kasei Pharma also appears in news items, including the planned relocation of its global R&D hub to Shonan Health Innovation Park to strengthen drug discovery and open innovation.
Within the Material sector, news coverage includes Asahi Kasei Microdevices (AKM) and its sensing technologies, such as millimeter-wave radar solutions for real-time swallowing detection, gesture recognition based on electromyography, and AgeTech and PetTech applications like fall detection, smart diapers, cage monitoring systems, and smart pet collars. Other articles highlight advanced materials, including PIMEL™ photosensitive dielectric recognized by a TSMC Excellent Performance Award, and battery-related innovations such as high ionic conductive electrolyte technology licensed to EAS Batteries.
Investors and followers of AHKSY can use this news stream to track Asahi Kasei’s portfolio transformation under its "Trailblaze Together" plan, including structural reforms like the divestiture of the Daramic lead battery separator business, the planned phase-out of hexamethylene diamine production, and the integration of Asahi Kasei Advance with Teijin Frontier. Bookmark this page to monitor ongoing developments in pharmaceuticals, critical care, electronics, advanced materials, and sustainability-related initiatives that Asahi Kasei highlights in its public communications.
Asahi Kasei (OTC:AHKSY) completed its acquisition of Aicuris, adding three antiviral assets to its pharmaceutical platform. Key assets include Prevymis® royalties (projected $100–$200M annually), pritelivir with FDA Priority Review and a PDUFA target in Q4 2026, and AIC468 (Phase I) for BK virus. Aicuris revenue is expected to reach $500M by 2030 (excluding AIC468). The company expects positive contributions to operating income after goodwill amortization from fiscal 2028 onward and will advance the portfolio via Veloxis Pharmaceuticals.
Asahi Kasei (OTC:AHKSY) announced initiation of a Phase I clinical trial for AK1940, a peptide-based TNF receptor 1 antagonist.
The trial began on April 19, 2026 in Japan (Trial ID: jRCT2071250141) to evaluate pharmacokinetics, safety, and tolerability after single and multiple subcutaneous doses in healthy volunteers. AK1940 was discovered jointly with PeptiDream and will be advanced by Asahi Kasei Therapeutics Corp.
Asahi Kasei Microdevices (AHKSY) and Kyoto University achieved laser oscillation in a 2 µm-band photonic crystal surface-emitting laser (PCSEL), enabling smaller, high-directionality, narrow-linewidth infrared sources.
AKM plans to accelerate R&D focused on manufacturability and advanced photonic crystal designs; results were presented at the Japan Society of Applied Physics Spring Meeting in March 2026.
Asahi Kasei (OTC:AHKSY), Nippon Steel, and Nippon Steel Trading launched a recycling initiative to remelt pure titanium scrap from chlor-alkali electrolysis cell production into new pure titanium. The process maintains strict traceability and digital control at Asahi Kasei’s Nobeoka site, with material collection, processing, and return to Nippon Steel for remelting.
The partners aim to raise recycling rates and link this work with prior closed-loop precious metals projects to reduce environmental impact and support circularity in the chlor-alkali industry.
Asahi Kasei (AHKSY) has begun installing an Aqualyzer™-C3 containerized 1 MW-class alkaline-water electrolyzer at Finland’s first commercial hydrogen refueling station in Jyväskylä. The system will produce 400 kg/day, supporting local hydrogen buses and fuel-cell vehicles with operations due in summer 2026.
The project is operated by Cefmof Hydrogen and is intended as a case model for hydrogen use in cold climates while showcasing Asahi Kasei's multi-modular, pressurized alkaline electrolysis approach and expanded 1–7.5 MW product range.
Asahi Kasei (OTC:AHKSY) agreed to acquire Aicuris for approximately €780 million (about $919 million) with closing expected in Q1 fiscal 2026, subject to customary conditions. The deal adds three anti-infective assets — Prevymis royalties, pritelivir (Phase III) and AIC468 (Phase I) — and targets synergy with transplant and nephrology franchises.
Asahi Kasei expects the acquisition to contribute positively to operating income from fiscal 2028 after amortization, and cites a strategy to reach ¥300 billion pharmaceutical net sales with an operating margin ≥15% by fiscal 2030.
Asahi Kasei Pharma (OTC:AHKSY) announced an exclusive global license agreement with Alchemedicine for novel preclinical lead compounds on February 3, 2026. The compounds, discovered via Alchemedicine’s HiSAP™ platform, target a single mechanism with potential for multiple autoimmune diseases.
The program is independent of a June 2022 deal and follows advancement of AK1960 to Phase I, reflecting deeper collaboration and a push toward Asahi Kasei Group’s $3 billion pharma sales goal by 2030.
Asahi Kasei Microdevices (OTC: AHKSY) announced that its 1983 commercialization of thin-film Hall elements has been designated an IEEE Milestone on February 19, 2026.
The announcement highlights AKM innovations—InSb thin-film placement and a three-layer electrode enabling gold wire bonding—and notes over 50 billion Hall sensor units shipped globally and broad adoption across consumer electronics, brushless motors, HVAC efficiency, smartphones, and EV systems.
Asahi Kasei Pharma (OTC:AHKSY) and Alchemedicine announced that the ETA receptor antagonist AK1960 has entered a Phase I clinical study after successful preclinical work. AK1960 showed potent, selective ETA inhibition and efficacy in animal kidney disease models; development leverages an exclusive 2022 license and partners Calliditas and Veloxis.
The program is presently conducting preclinical and Phase I work in Japan with a global commercialization intent.
Asahi Kasei (OTC: AHKSY) announced a new PFAS-free polyamide (PA66) engineered for low-friction, high-load sliding applications. The material delivers stable performance in dry, high-temperature, and high-load conditions and is offered in unreinforced and reinforced grades with customizable properties via processing control technology.
Target uses include gears, chain guides, and other sliding components where oil or grease cannot be used; tailored formulations adjust filler content, stiffness, heat resistance, and wet-condition behavior to aid PFAS phase-out.